title: Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.
abstract: To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: St Paul's Hospital, University of British Columbia, Vancouver, Canada.
authors.forename: K
authors.initials: K
authors.lastname: Gelmon
authors.forename: J S
authors.initials: JS
authors.lastname: Montaner
authors.forename: M
authors.initials: M
authors.lastname: Fanning
authors.forename: J R
authors.initials: JR
authors.lastname: Smith
authors.forename: J
authors.initials: J
authors.lastname: Falutz
authors.forename: C
authors.initials: C
authors.lastname: Tsoukas
authors.forename: J
authors.initials: J
authors.lastname: Gill
authors.forename: G
authors.initials: G
authors.lastname: Wells
authors.forename: M
authors.initials: M
authors.lastname: O'Shaughnessy
authors.forename: M
authors.initials: M
authors.lastname: Wainberg
mesh_terms: D000328:Adult; D002170:Canada; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions; D005221:Fatigue / Q000139:chemically induced; D015658:HIV Infections / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006716:Homosexuality; D006801:Humans; D008297:Male; D019964:Mood Disorders / Q000139:chemically induced; D015337:Multicenter Studies as Topic; D009325:Nausea / Q000139:chemically induced; D011537:Pruritus / Q000139:chemically induced; D011897:Random Allocation; D013997:Time Factors; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D015215:Zidovudine